Immune Design (IMDZ) Earning Somewhat Favorable Press Coverage, Study Shows
News coverage about Immune Design (NASDAQ:IMDZ) has trended somewhat positive on Monday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immune Design earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.547622049757 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Immune Design Corp (IMDZ) Expected to Post Earnings of -$0.39 Per Share (americanbankingnews.com)
- Immune Design Corp.,(NASDAQ: IMDZ),Mellanox Technologies, Ltd., (NASDAQ: MLNX), Flotek Industries, Inc., (NYSE … – Hot Stocks In Focus (press release) (reagentsglobalmarket.com)
- Short Interest in Immune Design Corp (IMDZ) Expands By 86.6% (americanbankingnews.com)
- Immune Design Corp (IMDZ) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
A number of brokerages have recently weighed in on IMDZ. Zacks Investment Research cut Immune Design from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. ValuEngine cut Immune Design from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Wells Fargo & Company cut Immune Design from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. Finally, Royal Bank Of Canada began coverage on Immune Design in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $13.19.
Immune Design (NASDAQ:IMDZ) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.11. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The firm had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million. equities analysts anticipate that Immune Design will post -1.89 earnings per share for the current year.
In other Immune Design news, Director Peter Svennilson bought 2,681,000 shares of the stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Lewis W. Coleman bought 50,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The stock was acquired at an average price of $4.50 per share, for a total transaction of $225,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 5,300,000 shares of company stock worth $21,874,900. 20.70% of the stock is owned by insiders.
Immune Design Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Stock Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related stocks with our FREE daily email newsletter.